Receiving three doses of inactivated or mRNA COVID-19 vaccines was associated with lower odds of long COVID symptoms among people with a history of SARS-CoV-2 infection in Hong Kong, China: a cross-sectional survey study

Epidemiol Infect. 2024 Dec 11:152:e166. doi: 10.1017/S0950268824001687.

Abstract

High prevalence of long COVID symptoms has emerged as a significant public health concern. This study investigated the associations between three doses of COVID-19 vaccines and the presence of any and ≥3 types of long COVID symptoms among people with a history of SARS-CoV-2 infection in Hong Kong, China. This is a secondary analysis of a cross-sectional online survey among Hong Kong adult residents conducted between June and August 2022. This analysis was based on a sub-sample of 1,542 participants with confirmed SARS-CoV-2 infection during the fifth wave of COVID-19 outbreak in Hong Kong (December 2021 to April 2022). Among the participants, 40.9% and 16.1% self-reported having any and ≥3 types of long COVID symptoms, respectively. After adjusting for significant variables related to sociodemographic characteristics, health conditions and lifestyles, and SARS-CoV-2 infection, receiving at least three doses of COVID-19 vaccines was associated with lower odds of reporting any long COVID symptoms comparing to receiving two doses (adjusted odds ratio [AOR]: 0.69, 95% CI: 0.54, 0.87, P = .002). Three doses of inactivated and mRNA vaccines had similar protective effects against long COVID symptoms. It is important to strengthen the coverage of COVID-19 vaccination booster doses, even in the post-pandemic era.

Keywords: Long COVID; booster; inactivated vaccines; mRNA vaccines; post-COVID-19 condition; post-acute sequelae of COVID-19; vaccination.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • COVID-19 Vaccines* / administration & dosage
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Cross-Sectional Studies
  • Female
  • Hong Kong / epidemiology
  • Humans
  • Male
  • Middle Aged
  • SARS-CoV-2* / immunology
  • Vaccines, Inactivated* / administration & dosage
  • Young Adult
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • Vaccines, Inactivated
  • mRNA Vaccines